03-20562. Government-Owned Inventions; Availability for Licensing

AGENCY:

National Institutes of Health, Public Health Service, DHHS.

ACTION:

Notice.

SUMMARY:

The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESS:

Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: [phone]; fax: [phone]. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Full-Length cDNA Clone Representing the Consensus Sequence of the RNA Genome of a Human Norovirus (strain MD145-12) that Encodes Biologically Active Proteins

Gael M. Belliot, Kim Y. Green, Stanislav V. Sosnovtsev (NIAID)

DHHS Reference No. E-212-2003/0

Licensing Contact: Sally Hu; 301/435-5606; [e-mail]

The invention provides for a full-length cloned cDNA copy of the RNA genome of a predominant norovirus strain designated MD145-12 that was associated with human gastrointestinal illness. The noroviruses, which were formerly known as “Norwalk-like” viruses are estimated to cause 23 million cases of acute gastroenteritis in the USA each year. The virus has been designated into category B of the CDC biodefense-related priority pathogens because it can be used as an agent of bioterrorism. The subject cDNA clone of the virus encodes proteins of the MD145-12 strain that, when expressed in vitro, exhibit properties that would be expected from those produced by the original infectious virus. This cDNA clone is presently the only source to obtain norovirus proteins to facilitate studies aimed at developing control strategies such as vaccines and therapeutic drugs.

It is our intention not to seek patent protection for the above described invention. Instead, the cDNA clone for norovirus strain MD145-12 is available for licensing via biological material license (BML).

Rapamycin Resistant T Cells and Therapeutic Uses Thereof

Drs. Daniel Fowler (NCI), Unsu Jung (NCI), Jeannie Hou (NCI), Ronald Gress (NCI), Bruce Levine (U. of Penn.), and Carl June (U. of Penn.)

U.S. Provisional Application Serial No. 60/478,736 filed 12 Jun 2003 (DHHS Reference No. E-063-2003/0-US-01)

Licensing Contact: Sally Hu; 301/435-5606; [e-mail]

This invention identified T cell culture conditions that use the immune suppression drug rapamycin (sirolimus) to generate rapamycin-resistant cells having Th1, Th2, Tc1 or Tc2 function (Th=T helper lymphocytes; Tc=cytotoxic T lymphocytes). This invention has demonstrated how to generate T cells enriched for Th1, Th2, Tc1 or Tc2 functions as well as how to control these functions in vivo. Those methods can make T cell therapies significantly more viable and applicable for treatment of a variety of diseases states, including cancer, infectious diseases, autoimmune diseases, Graft vs. Host Disease (GVHD) associated with allogeneic hematopoietic stem cell transplantation, and graft rejection. Thus, this invention has many useful purposes that could generate significant interest among groups pursuing immune therapies, particularly T cell-based therapeutic approaches. Diseases in which T cell based therapies would be of major impact include cancer, viral infections such as HIV disease, autoimmunity, transplantation and any other disease in which the T cells participate.

Computational Prediction Method for T Cell Epitopes Based on Quantitative Properties of MHC Binding Peptides

Myong-Hee Sung and Richard Simon (NCI)

U.S. Provisional Application Serial No. 60/416,034 filed 03 Oct 2002 (DHHS Reference No. E-110-2002/0-US-01)

Licensing Contact: Cristina Thalhammer-Reyero; 301/435-4507; [e-mail]

NIH announces a computational method for the prediction of peptides binding to major histocompatibility complex proteins (MHC), which facilitates the resource-consuming effort required to identify T-cell epitopes. The presentation of such epitopes by the MHC to T-cells can, in conjunction with co-factor interactions, activate the T-cells to initiate the necessary immune response against the epitope source. Consequently, peptides that are predicted to bind to multiple MHC molecules are potentially useful in vaccine design. The invention describes a new method for predicting MHC binding based on peptide property models constructed using biophysical parameters of the constituent amino acids and a training set of known binders. For example, the models can be applied to development of anti-tumor vaccines by scanning proteins over-expressed in cancer cells for peptides that bind to a variety of MHC molecules, as illustrated in the context of identifying candidate T-cell epitopes for melanomas and breast cancers. This computational approach provides an efficient and focused strategy for identifying candidate epitopes for development of vaccines and anti-cancer immunotherapy.

Dated: August 4, 2003.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.